Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
Status:
Recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial
hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia,
with an increase in erythrocyte mass, which predisposes to thrombotic complications.
Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with
described effects of reduction in erythrocyte and platelet aggregation, adhesion and
activation of leukocytes, and endothelial damage. The main objective of this study is to
verify if the chronic oral administration of pentoxifylline to Eisenmenger patients induces
an increase in the circulating levels of thrombomodulin, a naturally occurring proteoglycan
with anticoagulant, anti thrombotic and anti-inflammatory properties.